Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992- 1998

New England Journal of Medicine

Volumn 340, Issue 20, 1999, Pages 1525-1532

  Smith, Kirk E ^a   Besser, John M ^b   Hedberg, Craig W ^b   Leano, Fe T ^b   Bender, Jeffrey B ^b   Wicklund, Julie H ^b   Johnson, Brian P ^b   Moore, Kristine A ^b   Osterholm, Michael T ^b  

^a MINNESOTA DEPARTMENT OF HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; ENROFLOXACIN; ERYTHROMYCIN; GREPAFLOXACIN; LEVOFLOXACIN; NALIDIXIC ACID; NORDIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CAMPYLOBACTER JEJUNI; CHICKEN; CONTROLLED STUDY; GRAM NEGATIVE INFECTION; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; TRAVEL;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-INFECTIVE AGENTS; BACTERIAL TYPING TECHNIQUES; CAMPYLOBACTER INFECTIONS; CAMPYLOBACTER JEJUNI; CASE-CONTROL STUDIES; CHICKENS; CIPROFLOXACIN; DRUG RESISTANCE, MICROBIAL; HUMANS; MEAT; MINNESOTA; NALIDIXIC ACID; POPULATION SURVEILLANCE; RISK FACTORS; TRAVEL;

EID: 0033586951     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199905203402001     Document Type: Article

References (37)

1. Foodborne Diseases Active Surveillance Network, 1996. MMWR Morb Mortal Wkly Rep 1997;46:258-61.
2. Tauxe RT. Epidemiology of Campylobacter jejuni infections in the United States and other industrialized nations. In: Nachamkin I, Blaser MJ, Tompkins LS, eds. Campylobacter jejuni: current status and future trends. Washington, D.C.: American Society for Microbiology, 1992:9-19.
3. Allos BM, Blaser MJ. Campylobacter jejuni and the expanding spectrum of related infections. Clin Infect Dis 1995;20:1092-9.
4. The choice of antibacterial drugs. Med Lett Drugs Ther 1998;40:33-42.
5. Blaser MJ. Campylobacter and related species. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995: 1948-56.
6. Guerrant RL. Inflammatory enteritides. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995:987-98.
7. Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. N Engl J Med 1991;324:384-94.
8. Piddock LJ. Quinolone resistance and Campylobacter spp. J Antimicrob Chemother 1995;36:891-8.
9. Murray PR, ed. Manual of clinical microbiology. 6th ed. Washington, D.C.: ASM Press, 1995:485-7.
10. Leuchtefeld N, Wang WL, Blaser M, Reller LB. Campylobacter fetus subsp. jejuni: background and laboratory diagnosis. Lab Med 1981;12: 481-6.
11. Performance standards for antimicrobial disk susceptibility tests. 6th ed. Approved standard. Document M2-A6 (M100-S7). Wayne, Pa.: National Committee for Clinical Laboratory Standards, 1997.
12. Huang MB, Baker CN, Banerjee S, Tenover FC. Accuray of the E test for determining antimicrobial susceptibilities of staphylococci, enterococci, Campylobacter jejuni, and gram-negative bacteria resistant to antimicrobial agents. J Clin Microbiol 1992;30:3243-8.
13. Performance standards for antimicrobial susceptibility testing: eighth informational supplement. Document M100-S8. Wayne, Pa.: National Committee for Clinical Laboratory Standards, 1998.
14. Nachamkin I, Bohachick K, Patton CM. Flagellin gene typing of Campylobacter jejuni by restriction length polymorphism analysis. J Clin Microbiol 1993;31:1531-6.
15. Hunt JM. Campylobacter. In: Food and Drug Administration. Bacteriological analytical manual. 7th ed. Arlington, Va.: AOAC International, 1992:77-91.
16. Minnesota health statistics, 1994. Minneapolis: Center for Health Statistics, Minnesota Department of Health, 1996.
17. Dean AG, Dean JA, Coulombier D, et al. Epi Info, version 6: a word processing program for public health on IBM-compatible microcomputers. Atlanta: Centers for Disease Control and Prevention, 1995.
18. SAS procedures guide, version 6. 3rd ed. Cary, N.C.: SAS Institute, 1990.
19. Jacobs-Reitsma WF, Kan CA, Bolder NM. The induction of quinolone resistance in Campylobacter bacteria in broilers by quinolone treatment. Lett Appl Microbiol 1994;19:228-31.
20. Endtz HP, Ruijs GJ, van Klingeren B, Jansen WH, van der Reyden T, Mouton RP. Quinolone resistance in Campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine. J Antimicrob Chemother 1991;27:199-208.
21. Reina J, Borrell N, Serra A. Emergence of resistance to erythromycin and fluoroquinolones in thermotolerant Campylobacter strains isolated from feces 1987-1991. Eur J Clin Microbiol Infect Dis 1992;11:1163-6.
22. Sanchez R, Fernandez-Baca V, Diaz MD, Munoz P, Rodriguez-Creixems M, Bouza E. Evolution of susceptibilities of Campylobacter spp. to quinolones and macrolides. Antimicrob Agents Chemother 1994;38:1879-82.
23. Velazquez JB, Jimenez A, Chomon B, Villa TG. Incidence and transmission of antibiotic resistance in Campylobacter jejuni and Campylobacter coli. J Antimicrob Chemother 1995;35:173-8.
24. Perez-Trallero E, Urbieta M, Lopategui CL, Zigorraga C, Ayestaran I. Antibiotics in veterinary medicine and public health. Lancet 1993;342: 1371-2.
25. Li CC, Chiu CH, Wu JL, Huang YC, Lin TY. Antimicrobial susceptibilities of Campylobacter jejuni and coli by using E-test in Taiwan. Scand J Infect Dis 1998;30:39-42.
26. Gaunt PN, Piddock LJV. Ciprofloxacin resistant Campylobacter spp. in humans: an epidemiological and laboratory study. J Antimicrob Chemother 1996;37:747-57.
27. Sjogren E, Lindblom GB, Kaijser B. Norfloxacin resistance in Campylobacter jejuni and Campylobacter coli isolates from Swedish patients. J Antimicrob Chemother 1997;40:257-61.
28. Bowler I, Day D. Emerging quinolone resistance in campylobacters. Lancet 1992;340:245.
29. Murphy GS Jr, Echeverria P, Jackson LR, Arness MK, LeBron C, Pitarangsi C. Ciprofloxacin-and azithromycin-resistant Campylobacter causing traveler's diarrhea in U.S. troops deployed to Thailand in 1994. Clin Infect Dis 1996;22:868-9.
30. Rautelin H, Renkonen OV, Kosunen TU. Emergence of fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli in subjects from Finland. Antimicrob Agents Chemother 1991;35:2065-9.
31. Slavin MA, Jennens I, Tee W. Infection with ciprofloxacin-resistant Campylobacter jejuni in travellers returning from Asia. Eur J Clin Microbiol Infect Dis 1996;15:348-50.
32. FAO yearbook, 1992-1997. FAO statistical series. Rome: Food and Agriculture Organization of the United Nations, 1993-1998.
33. Mercadeo Estadistico. Colonia Minerva, Mexico: Mercadeo Estadistico, 1994-1998 (software).
34. Goodman LJ, Trenholme GM, Kaplan RL, et al. Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults. Arch Intern Med 1990;150:541-6.
35. Wistrom J, Jertborn M, Ekwall E, et al. Empiric treatment of acute diarrheal disease with norfloxacin: a randomized, placebo-controlled study: Swedish Study Group. Ann Intern Med 1992;117:202-8.
36. Threlfall EJ, Frost JA, Ward LR, Rowe B. Increasing spectrum of resistance in multiresistant Salmonella typhimurium. Lancet 1996;347:1053-4.
37. Glynn MK, Bopp C, Dewitt W, Dabney F, Mokhtar M, Angulo FJ. Emergence of multidrug-resistant Salmonella enterica serotype typhimurium DT104 infections in the United States. N Engl J Med 1998;338:1333-8.